Epicatechin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
In people, small studies of the pure compound found a small drop in fasting insulin at 100 mg a day and nothing at 25 mg a day.
Evidence grade for Epicatechin: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 4 completed trials, 44 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 44
- Human studies
- 4
- Found nothing
- 2
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
4 completed trials, 44 people given it
1 effects reported, 1 unwanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Muscle and strength, Ageing and longevity, Injury, healing and recovery, Heart and circulation, Immune system and inflammation, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Epicatechin is a plant compound found in cocoa. It is sold as a pill. People buy it for blood flow, blood sugar and muscle. It is a supplement, not a drug.
What people take it for
- Bigger muscles, because of claims that it lowers myostatin.
- Better blood flow, since it is the part of cocoa that widens arteries for a few hours.
- Better blood sugar.
- A longer life, after a mouse study.
What studies in people showed
The studies in people are small and short. A review of 11 trials found one steady result. Arteries widen more for a few hours after a dose, in healthy young adults. In 48 overweight adults, 25 mg a day for two weeks did nothing. In 37 adults with slightly high blood pressure, 100 mg a day for four weeks cut fasting insulin a little. Blood pressure did not change. The muscle claims come from a 7 day study and a study of 7 people with a muscle disease. Neither had a group to compare with. Now mice. In male mice, it made the typical lifespan about 5 percent longer. Female mice got nothing. It has been tested once.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- The human studies on this page do not report side effects. We have no user reports on problems either.
Where these come from: No user reports. The notes above come from the studies on this page.
My bottom line
The muscle story rests on seven people and no group to compare with. If you want muscle, lift and eat your protein. I would not pay for this to live longer on one mouse result in males.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Epicatechin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Blood sugar and insulin37 people · 2 studies · 2 found nothing
- Blood pressure37 people · 2 studies · 2 found nothing
- Cell energy and mitochondria7 people · 1 study
- Cholesterol and blood fatsno headcount stated · 1 study · 1 found nothing
- Getting strongerno headcount stated · 1 study
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Living longer1 animal or lab study
27 of the 36 indexed goals have no study of any kind behind Epicatechin
No study in people, animals or cells on this page reports a result for these. That does not prove Epicatechin does nothing for them. It does mean anything you have heard about Epicatechin and one of these did not come from a study cited here.
Show full evidence
What is Epicatechin?
In people, small studies of the pure compound found a small drop in fasting insulin at 100 mg a day and nothing at 25 mg a day. Its fame for better blood flow comes mostly from a short-term response to cocoa drinks. In male mice, it made typical lifespan 5 percent longer in the 2021 run of the NIA mouse lifespan program. Female mice saw no change.
Epicatechin is a plant compound found in cocoa. It gets most of the credit for cocoa's name as good for blood vessels. It is sold as a pure supplement. Much of the buzz comes from a 2014 report on a handful of people. After a week on it, their grip got stronger and two muscle signal proteins shifted, follistatin up against myostatin. A 2006 study also found it was the part of cocoa behind the quick widening of arteries after a cocoa drink.
Studies of the pure compound in people are small and mixed. In 37 adults aged 40 to 80 with slightly high blood pressure, 100 mg a day for four weeks did not clearly change how well arteries widen. The small rise, 1.1 percentage points, could have been chance. Blood pressure did not change. Fasting insulin fell by 1.46 mU/L, and a score of insulin resistance fell by 0.38. In 48 overweight or obese adults with signs of metabolic syndrome, 25 mg a day for two weeks changed nothing. Blood pressure, blood sugar, insulin, blood fats and damaged LDL all stayed the same. A 2022 review looked at 11 trials of epicatechin itself. The only steady finding was a short-term rise in artery widening in healthy young adults, bigger at bigger doses. The reviewers said most of the trials had some risk of bias.
In mice, the NIA's lifespan program fed epicatechin from 7 months of age. Males lived longer. Their typical (median) lifespan was 836 days against 794, a 5.3 percent gain. Survival to old age, measured at the age when only 10 percent of mice are usually still alive, rose 6.2 percent. The trend showed at all three labs. Females showed nothing (median down 2.2 percent). The paper's main text does not give the dose in the food. It is in the extra tables.
Epicatechin is a food ingredient and a supplement. It is not an approved drug anywhere. A small company made a lab-built mirror image form, called (+)-epicatechin. It gave it to 22 people with Becker muscular dystrophy in an early safety study, and to 10 people with Friedreich ataxia in a small study where everyone got it. That is a different molecule from the (-)-epicatechin in cocoa and in most supplements.
How does Epicatechin work?
In people, a cocoa drink rich in flavanols quickly raises nitric oxide in the blood. Nitric oxide relaxes blood vessels, so arteries widen more. Epicatechin and one of its breakdown products were the parts of the drink that tracked this effect. Pure epicatechin did the same thing. Blocking the body's nitric oxide maker stopped it. In seven adults with Becker muscular dystrophy, 50 mg twice a day for eight weeks raised muscle signals tied to energy use and to building new mitochondria, the cell's power plants. Muscle samples showed more of the folds inside mitochondria where energy is made. Follistatin went up and myostatin, a brake on muscle growth, went down. Everyone knew they were taking it, and there was no comparison group. In lab rodents, epicatechin boosts signals for new blood vessels and new mitochondria in muscle, and the animals run longer on a treadmill. That is why the mouse lifespan program picked it. Nobody knows why the lifespan gain showed up only in males. The same male lean runs through most of the program's wins, and nobody has explained it.
What have studies in people found about Epicatechin?
Real but small. Pure epicatechin has been tested in people in about a dozen trials. All were short, from days to four weeks. None had more than about 50 people. There are also muscle studies of seven or fewer people where everyone got it. Cocoa studies are much bigger, but they cannot pin the effect on epicatechin alone.
- A review of 11 trials of pure epicatechin: the only steady finding was a short-term rise in artery widening in healthy young adults.
- A review of 16 cocoa trials estimated that 25 mg a day of epicatechin, eaten as cocoa, went with about 4 mmHg lower top number blood pressure. That is cocoa, not the pure compound. The pure compound at that dose did nothing in the 48 person trial below.
- 48 overweight or obese adults took 25 mg a day for 2 weeks, and a dummy pill for 2 weeks, in turn: no effect on any heart or blood sugar measure.
- 37 adults aged 40 to 80 with slightly high blood pressure took 100 mg a day for 4 weeks, and a dummy pill in turn. Artery widening did not clearly change. Fasting insulin fell 1.46 mU/L and an insulin resistance score fell 0.38. Blood pressure and blood fats did not change.
- Muscle: a 7 day first look reported a stronger grip and a higher follistatin to myostatin ratio. In 7 adults with Becker muscular dystrophy, 50 mg twice a day for 8 weeks moved markers of mitochondria and muscle repair. Neither study had a comparison group.
- No study in people has measured anything to do with ageing, and none ran longer than a few months.
What this does not tell you: Nothing here shows that epicatechin changes how long or how well a person lives. The one steady finding in people is a short-term blood vessel response. The insulin drop comes from one 37 person study, and a lower dose did not repeat it. The muscle claims rest on seven or fewer people with no comparison group. The mouse lifespan gain was in males only, and the human studies did not look at men and women separately.
The state of the research
The National Institute on Aging runs a mouse lifespan program called the Interventions Testing Program. It tests each compound at three labs at the same time: The Jackson Laboratory, the University of Michigan and UT Health San Antonio. The mice are a mixed breed, so a result is less likely to be a quirk of one strain. Males and females are both tested and judged separately. The three labs' results are then pooled. Every result gets published, whether or not the compound worked. It runs on public money from the National Institute on Aging, with no drug company money. In the 2021 run, epicatechin made typical (median) male lifespan 5.3 percent longer. Survival to old age rose 6.2 percent. The trend pointed the same way at all three labs. It did nothing in females. That is a modest but real result, in the program built to catch results that do not repeat. It has been tested once, at one dose, from one starting age. The program has often seen a win at one dose or age fail at another. Astaxanthin, meclizine and mitoglitazone all failed retests in the 2022 run. So treat this as a first result, not a confirmed one.
The record in people is thin for the usual money reason, and one more. Nobody can patent epicatechin, so nobody will pay for a big trial. The food industry money that exists has gone into cocoa products, not the pure compound. That is why the big cocoa studies cannot say the effect came from epicatechin. Without trials, both benefit and harm go unmeasured. The 2022 review put it honestly. It is unclear whether epicatechin does nothing for most measures, or whether the trials were too small to see it.
The evidence, in charts
Fig. 1a · how many people
44people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| American Journal of Clinical Nutrition 2015 | 37 | 84% |
| Muscle and Nerve 2021 | 7 | 16% |
One study holds 84% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 4 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
6 of 8 sources here are studies in people. The rest are not.
- Study in people · done in people675%
- Animal study · done in animals113%
- Review of studies · sums up other studies113%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 7 different years, 2006 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Supplement
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Epicatechin, which is expected: a supplement is not built from amino acids.
The studies we cite
- Study in people2015Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial
Pure epicatechin did not improve blood vessel function, and the small insulin change is easy to over-read. 37 adults aged 40 to 80 with raised blood pressure took 100 mg a day for four weeks, and each also took a dummy for four weeks, in turn. Artery widening improved slightly, too little to separate from chance. Fasting insulin fell a little. Blood pressure, artery stiffness and cholesterol did not budge. No funding was stated in the abstract retrieved.
37 adults aged 40 to 80 with systolic pressure 125 to 160 mmHg, 100 mg (-)-epicatechin a day for 4 weeks in crossover. Flow-mediated dilation: +1.1 percentage points, 95 percent CI -0.1 to 2.3, p = 0.07, not significant. Fasting insulin fell 1.46 mU/L (p = 0.03) and HOMA-IR fell 0.38 (p = 0.04). No change in blood pressure, arterial stiffness or lipids. Funding not stated in the abstract retrieved.
- Study in people2018A nutritive dose of pure (-)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults: a randomized, placebo-controlled, double-blind crossover study
A food-sized dose of pure epicatechin did nothing. 48 overweight or obese non-smokers with features of metabolic syndrome took 25 mg a day for two weeks, and each took a dummy for two weeks as well, in turn. Nothing moved: not blood pressure, glucose, insulin, triglycerides, or any cholesterol measure. The authors conclude that whatever cocoa does, epicatechin alone does not explain it. Two weeks is short, and the dose was deliberately a dietary one.
48 overweight or obese non-smokers aged 20 to 65 with features of metabolic syndrome, 25 mg (-)-epicatechin a day for 2 weeks in crossover. No significant effect on blood pressure, glucose, insulin, HOMA-IR, triglycerides, total, LDL or HDL cholesterol, or oxidised LDL. The authors conclude the cocoa effect cannot be ascribed to epicatechin alone.
- Study in people2006(-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans
This is the study the epicatechin reputation rests on, and it used cocoa, not a supplement. Healthy men drank a cocoa drink rich in flavanols. Nitric oxide in the blood and artery widening rose within hours. Epicatechin and one of its breakdown products were the parts that tracked the effect. Pure epicatechin did the same thing, and blocking the body's nitric oxide maker stopped it. It looked at one sitting, not weeks of use. It shows how it works, not a lasting benefit.
In healthy men, flavanol-rich cocoa acutely raised circulating nitric oxide species and flow-mediated dilation; (-)-epicatechin and its 7-O-glucuronide were the independent predictors, pure (-)-epicatechin reproduced the effect, and nitric oxide synthase inhibition abolished it. The mechanistic paper behind the supplement's reputation.
- Study in people2014Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation
This is the study most supplement marketing traces back to, and it cannot carry that weight. Alongside mouse work, a first look in people gave epicatechin for seven days and reported stronger hand grip and a shift in two muscle-signalling proteins. Nobody went without the compound, so there is nothing to compare against. Seven days is not long enough for muscle to change. Treat it as a first hint, not a result.
Mouse data plus an initial proof-of-concept in humans: 7 days of (-)-epicatechin increased hand grip strength and the plasma follistatin to myostatin ratio. Small, uncontrolled and short; this is the study most supplement marketing traces back to.
- Study in people2021(-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy
In a muscle-wasting disease, epicatechin moved the biology, but nobody went without it. Seven adults with Becker muscular dystrophy who could still walk took 50 mg twice a day for eight weeks, with a muscle sample taken before and after. Markers of mitochondrial building and muscle repair rose, myostatin fell, and heart rate and lactate at set workloads came down. Everybody knew they were taking it and there was no comparison group, so no way to know what would have happened anyway.
Open-label, 7 ambulatory adults, 50 mg twice daily for 8 weeks with biceps biopsy before and after. Increased LKB1, AMPK, PGC-1alpha, cristae abundance, follistatin and regeneration markers; myostatin fell; heart rate and lactate at fixed workloads fell. No placebo group.
- Study in people2022Safety and biomarker response to (+)-epicatechin in Becker muscular dystrophy
A company study of the mirror-image molecule finished and has published nothing. Epirium Bio gave 22 participants rising doses of the synthetic plus form, with everybody knowing what they were taking, and completed it in March 2022. No results were posted on the registry when this page was reviewed. Note also that the molecule differs from the epicatechin sold as a supplement.
Phase 1 open-label dose escalation of the synthetic (+) enantiomer in 22 participants, sponsored by Epirium Bio, completed March 2022. No results posted on the registry at the time of review.
- Review of studies2022Effect of an (-)-epicatechin intake on cardiometabolic parameters: a systematic review of randomized controlled trials
A review of 11 trials of pure epicatechin found almost nothing. The one steady result was a short-term rise in artery widening in healthy young adults, bigger at bigger doses. Blood vessels, blood sugar, blood fats, inflammation, appetite and weight did not change otherwise. Most of the trials had some risk of bias.
11 randomised trials of epicatechin itself. Apart from a dose-dependent acute increase in flow-mediated dilation and peripheral arterial tonometry in healthy young adults, no effects were observed on vascular, glucose, lipid, oxidative stress, inflammation, appetite or body weight endpoints. Most trials rated as having some risk of bias.
- Animal study2026Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice
In mice. In the 2021 run of the NIA mouse lifespan program, epicatechin was fed from 7 months of age. The typical male lived 836 days against 794, a 5.3 percent gain. Survival to old age rose 6.2 percent. There were 141 treated males and 298 untreated ones. Females did not live longer (typical lifespan down 2.2 percent). Public NIA money paid for it.
Interventions Testing Program 2021 cohort, treatment from 7 months. Male median lifespan 836 versus 794 days (+5.3 percent, log-rank p = 0.037), 90th percentile survival +6.2 percent (p = 0.01); 141 treated males against 298 controls. Females: median -2.2 percent, p = 0.6. NIA funded.
Common questions
Has Epicatechin been tested in people?
Yes. 44 people given it across 4 completed trials cited here, 2 of which found nothing. In people, small studies of the pure compound found a small drop in fasting insulin at 100 mg a day and nothing at 25 mg a day.
What is the Epicatechin dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 4 completed trials, 44 people given it
Is Epicatechin FDA-approved?
Not an approved drug. Sold as a dietary supplement and present in cocoa. The lifespan result is in male mice only. (+)-Epicatechin, a lab-made mirror-image form, is investigational for muscular dystrophy.
Did epicatechin extend lifespan in the ITP?
In male mice, yes. Typical lifespan rose 5.3 percent (836 against 794 days), and survival to old age rose 6.2 percent, when feeding began at 7 months. In female mice it did nothing. It has been tested once. Other wins in the same program have failed when retested at a different dose or starting age.
Does epicatechin improve blood vessel function in people?
In the short term, yes. After a cocoa drink or a single pure dose, arteries widen more. That is well shown in healthy young adults. Over four weeks, 37 middle-aged adults took 100 mg a day. Artery widening rose 1.1 percentage points, too little to rule out chance. Blood pressure did not change in either study of the pure compound.
Does it build muscle or lower myostatin?
A 7 day first look reported a stronger grip and a higher follistatin to myostatin ratio. An 8 week study in 7 adults with Becker muscular dystrophy pointed the same way, with changes in muscle samples. Neither had a dummy pill group, and neither measured muscle size. No study with a comparison group has tested this claim.
What dose was used in the human trials?
25 mg a day did nothing in 48 overweight adults over 2 weeks. 100 mg a day lowered insulin in 37 adults over 4 weeks, but did not clearly change artery widening. The muscular dystrophy study used 50 mg twice a day. No trial has run longer than a few months.